Key result
Review contrasts strict blood pressure lowering with the J-curve argument and updates the HOT Study.
Why the study?
Treated hypertensive patients remain at increased cardiovascular risk possibly due to blood pressure not being lowered to strictly normotensive levels, despite concerns about excessive lowering increasing risks.
Does vigorous lowering of blood pressure to strictly normotensive levels reduce cardiovascular morbidity and mortality in hypertensive patients?
Does vigorous lowering of blood pressure to strictly normotensive levels reduce cardiovascular morbidity and mortality in hypertensive patients?
Answers are grounded in this paper and cite their sources.
This review discusses the rationale and ongoing trials (BBB and HOT) investigating whether strictly normalizing blood pressure in hypertensive patients improves cardiovascular outcomes or poses risks due to a J-curve effect.
Several large intervention trials in hypertension have shown that treated hypertensive patients are at increased risk of cardiovascular morbidity and mortality in spite of being treated. One possible explanation for this is the fact that the treated blood pressure rarely if ever is brought down to strictly normotensive levels. Against this view is the J-curve argument that suggests that too vigorous lowering of blood pressure may increase cardiovascular risks. Two prospective intervention trials have addressed this problem, the BBB Study, which has been published, and the much larger HOT Study which is still ongoing. Some of the findings in these two trials will be discussed with an emphasis on giving an up-date of the HOT Study.
No takes yet. Share an insight, caveat, or question.
Lennart Hansson (1996) conducted a review in hypertension. Vigorous blood pressure lowering was evaluated. A review of the rationale for strictly lowering blood pressure to normotensive levels versus the J-curve argument, with an update on the ongoing HOT Study.
Synapse has enriched 10 related papers. Consider them for comparative context: